Tempramed receives Chinese patent for Vivi Box

Mr. Ron Nagar reports TEMPRAMED STRENGTHENS GLOBAL INTELLECTUAL PROPERTY POSITION WITH GRANTED CHINESE PATENT FOR NEWEST PRODUCT, VIVI BOX Tempramed Technologies Ltd.'s Chinese patent application No. 202310499587.4 has been formally granted by the China National Intellectual Property Administration. The patent, filed on Oct. 24, 2019, was granted on March 17, 2026. The patent includes claims covering key aspects of the company's first-of-its-kind, multimedication storage box, Vivi Box, which the company is planning to launch to market at the end of 2026. Once launched, it will add to the existing portfolio of four products being sold in market. There are also many commercial application opportunities with the Vivi Box, which the company has started exploring. Without limiting the scope of the patent, it includes core elements of Tempramed's proprietary thermal insulation and smart monitoring architecture, such as: Continuous temperature protection during power interruptions or refrigerator temperature fluctuations for several medication devices and vials; Portable, all-day travel functionality for secure on-the-go cold storage; Smart content tracking with cloud-based data integration, supporting adherence and remote monitoring. These capabilities position Vivi Box as a differentiated platform at the intersection of home health, smart refrigeration and the connected medical device ecosystem. The innovation supports Tempramed's strategy to expand beyond single injection protection into scalable, multidose and multiformat medication storage systems -- an important pillar of the company's long-term commercialization road map. "The formal grant of our Chinese patent represents a significant milestone in Tempramed's global intellectual property strategy," said Ron Nagar, chief executive officer of Tempramed. "China is one of the most influential markets globally for advanced health care solutions and smart appliance integration. Securing patent protection in this jurisdiction meaningfully strengthens our position and expands our presence comprehensive product portfolio across Asia." "The Vivi Box will add to our existing portfolio of products we already have on the market, with our proprietary technology at the core of all of them. As we continue to build out new product categories and scale our platform, protecting our core innovations remains fundamental to unlocking long-term shareholder value and establishing global leadership in temperature-controlled medication management," commented Mr. Nagar. This new grant follows a series of recent milestones for Tempramed, including the grant of a similar patent in South Korea, entering into several distribution agreements and validation of its return on investment model for insurance payers as verified by hundreds of clinicians recommending Tempramed's Vivi Cap to patients. Together, these achievements support the company's multiyear strategy to scale globally, introduce new product categories and establish Tempramed as one of the worldwide leaders in temperature-regulated medication protection and management. About Tempramed Technologies Ltd. Tempramed is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered, thermal insulation devices that work 24-seven without batteries or external power. With a product line already in market, including Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed will continue to expand globally offering a solution for medication protection and adherence. We seek Safe Harbor.